酪氨酸激酶抑制剂仑伐替尼通过靶向肿瘤微环境中的周细胞抑制未分化甲状腺癌生长
研究评估未分化甲状腺癌(ATC)中周细胞富集情况,以及仑伐替尼对与周细胞共培养的ATC细胞和共植入周细胞的人BRAFWT/V600E-ATC细胞异种移植小鼠模型的作用。结果显示ATC样本周细胞显著富集,BRAFWT/V600E-ATC细胞对仑伐替尼耐药,但与周细胞共培养后敏感性增加、细胞数减少;共植入周细胞促进ATC生长且未下调微环境TSP-1。作者认为周细胞存在可能对ATC患者仑伐替尼有效治疗至关重要。
要点
- ATC样本较正常甲状腺样本周细胞显著富集。
- BRAFWT/V600E-ATC细胞对仑伐替尼耐药,MAPK和Akt通路未被抑制。
- ATC细胞与周细胞共培养后对仑伐替尼敏感性增加、细胞数减少。
核心结论
- ATC样本中周细胞富集,仑伐替尼在有周细胞存在时对BRAFWT/V600E-ATC细胞显示抑制作用。
- 作者认为周细胞存在可能对ATC患者仑伐替尼有效治疗至关重要,周细胞丰度程度可能是评估药物治疗选择的预后标志物。
研究设计与样本
- 评估ATC样本中周细胞富集情况,并检测仑伐替尼对与周细胞共培养的ATC细胞及共植入周细胞的人BRAFWT/V600E-ATC细胞异种移植小鼠模型的作用。
主要发现
- ATC样本较正常甲状腺样本周细胞显著富集。
- BRAFWT/V600E-ATC细胞对仑伐替尼耐药,表现为MAPK和Akt通路未被抑制。
- 仑伐替尼随时间增加CD47蛋白(TSP-1受体)水平 vs 对照,TSP-1水平在仑伐替尼晚期 vs 早期时间点下调。
- ATC细胞与周细胞共培养后对该治疗敏感性增加,最终细胞数减少。
- 体内共植入ATC细胞与周细胞增加ATC生长,且未下调体内微环境中的TSP-1。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Anaplastic thyroid carcinoma (ATC) is a rapidly fatal cancer with a median survival of a few months. Enhanced therapeutic options for durable management of ATC will rely on an understanding of genetics and the role of the tumor microenvironment. The prognosis for patients with ATC has not improved despite more detailed scrutiny of underlying tumor genetics. Pericytes in the microenvironment play a key evasive role for thyroid carcinoma (TC) cells. Lenvatinib improves outcomes in patients with radioiodine-refractory well-differentiated TC. In addition to the unclear role of pericytes in ATC, the effect and mechanism of lenvatinib efficacy on ATC have not been sufficiently elucidated. Design: We assessed pericyte enrichment in ATC. We determined the effect of lenvatinib on ATC cell growth cocultured with pericytes and in a xenograft mouse model from human BRAFWT/V600E-ATC-derived cells coimplanted with pericytes. Results: ATC samples were significantly enriched in pericytes compared with normal thyroid samples. BRAFWT/V600E-ATC-derived cells were resistant to lenvatinib treatment shown by a lack of suppression of MAPK and Akt pathways. Moreover, lenvatinib increased CD47 protein (thrombospondin-1 [TSP-1] receptor) levels over time vs. vehicle. TSP-1 levels were downregulated upon lenvatinib at late vs. early time points. Critically, ATC cells, when cocultured with pericytes, showed increased sensitivity to this therapy and ultimately decreased number of cells. The coimplantation in vivo of ATC cells with pericytes increased ATC growth and did not downregulate TSP-1 in the microenvironment in vivo. Conclusions and Implications: Pericytes are enriched in ATC samples. Lenvatinib showed inhibitory effects on BRAFWT/V600E-ATC cells in the presence of pericytes. The presence of pericytes could be crucial for effective lenvatinib treatment in patients with ATC. Degree of pericyte abundance may be an attractive prognostic marker in assessing pharmacotherapeutic options. Effective durable management of ATC will rely on an understanding not only of genetics but also on the role of the tumor microenvironment.
引用
- Iesato A, Li S, Sadow PM, et al. The Tyrosine Kinase Inhibitor Lenvatinib Inhibits Anaplastic Thyroid Carcinoma Growth by Targeting Pericytes in the Tumor Microenvironment. Thyroid. 2023. PMID: 37171127. doi:10.1089/thy.2022.0597
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。